Open access

Clinicopathological Features of DLL3 Expression and T‐Cell Infiltration in LCNEC: Insights From Pathology and Clinical Response to Tarlatamab

S. Kaneko Naoki Furuya Y. Sugiura H. Tsuruoka Kazuhiro Nishiyama Honoka Morita Tomoki Okura H. Saji J. Koike N. Ohike M. Mineshita

Oct 2026 · Thoracic Cancer · Vol 17 · 0 citations · 38 references

Medicine

TL;DR

Evaluated DLL3 expression and CD8+ tumor‐infiltrating lymphocytes (TILs) infiltration in LCNEC and investigated their clinical significance and association with tarlatamab efficacy.

Abstract

Large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive lung neuroendocrine neoplasm with poor prognosis. Recently, DLL3‐targeted bispecific T‐cell engagers (BiTEs) have shown promising efficacy in small cell lung cancer, and clinical trials are ongoing in LCNEC. This study evaluated DLL3 expression and CD8+ tumor‐infiltrating lymphocytes (TILs) infiltration in LCNEC and investigated their clinical significance and association with tarlatamab efficacy.

DOI PubMed Semantic Scholar

Read PDF

Similar papers

Open access Oct 2026

Zanubrutinib monotherapy in CD79B‐mutated relapsed or refractory diffuse large B‐cell lymphoma: A multicenter Phase 2 study

Diffuse large B ‐ cell lymphoma (DLBCL) remains a clinically and molecularly heterogeneous disease, 1 with approximately one ‐ third of patients developing relapsed or refractory (R/R) disease following frontline immunochemotherapy. 2,3 Among molecularly defined sub-groups, CD79B mutations occur in 5% – 25% of DLBCL

Li Wang, K. Zhou, Fei Li et al. · HemaSphere · 0 citations

Open access Sep 2026

EZH2 expression in diffuse large B-cell lymphoma: clinicopathological associations and relationship with survival

Purpose: Enhancer of zeste homolog 2 (EZH2) is an epigenetic regulator implicated in the pathogenesis of diffuse large B-cell lymphoma, but the prognostic value of its protein expression is uncertain. We evaluated EZH2 expression and its associations with clinicopathological features and survival.Materials and Methods:...

Mehmet Mutlu Kıdı, Mehmet Turker, Sedat Biter et al. · Cukurova Medical Journal · 0 citations

Open access 2026

Identification of TXNDC16 Expression Pattern in Small Cell Lung Cancer

: Background: Small cell lung cancer (SCLC) is an aggressive malignancy characterized by rapid progression, early metastasis, and molecular heterogeneity. Neuroendocrine (NE) and non-neuroendocrine (non-NE) SCLC subtypes differ in transcriptional programs related to Achaete-scute homolog 1 (ASCL1), Neurogenic different...

Anna M. Dmitrieva, Qian Yang, Ramona Lesch et al. · Oncology Research · 0 citations

Open access Sep 2026

Tarlatamab: Invaluable Time for Patients With Extensive-Stage Small Cell Lung Cancer.

Extensive-stage small cell lung cancer (ES-SCLC) remains highly aggressive and has a poor prognosis. Tarlatamab-dlle (tarlatamab), a bispecific T-cell engager targeting delta-like ligand 3, offers a novel therapeutic option f.

Elizabeth Jane Entrop, Casey B. Brown · Clinical Journal of Oncology... · 0 citations

Open access Oct 2026

Aggressive features and immune landscape of macrotrabecular hepatocellular carcinoma

Highlights • MT-HCC exhibits more aggressive clinical and pathological features than CV-HCC.• Higher AFP, larger tumor size and more vascular invasion are observed in MT-HCC.• Distinct immune cell distribution patterns are identified in different tumor regions.• CD20+ B cells in the tumor margin correlate with favorabl...

Li-Xia Wu, Mei-Dan Li, Xue-Fang Wang et al. · Translational Oncology · 0 citations

Review Open access Oct 2026

Efficacy and Safety of CAR T‐Cell Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review and Meta‐Analysis

Patients with relapsed or refractory primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL) have limited treatment options and poor outcomes. CD19‐directed chimeric antigen receptor (CAR) T‐cell therapy has shown promising activity in this setting; however, the available e...

Anfal Khan, A. A. Malik, Waqas Kareem et al. · eJHaem · 0 citations